Breast epithelial cell proliferation is markedly increased with short-term high levels of endogenous estrogen secondary to controlled ovarian hyperstimulation by Chung, Karine et al.
EPIDEMIOLOGY
Breast epithelial cell proliferation is markedly increased
with short-term high levels of endogenous estrogen secondary
to controlled ovarian hyperstimulation
Karine Chung • Linda J. Hovanessian-Larsen • Debra Hawes • DeShawn Taylor •
Susan Downey • Darcy V. Spicer • Frank Z. Stanczyk • Sherfaraz Patel •
A. Rebecca Anderson • Malcolm C. Pike • Anna H. Wu • Celeste Leigh Pearce
Received: 31 October 2011/Accepted: 1 November 2011/Published online: 15 November 2011
 The Author(s) 2011. This article is published with open access at Springerlink.com
Abstract Oocyte donors have high serum estradiol (E2)
levels similar to the serum levels seen in the ﬁrst trimester
of pregnancy. We report in this article our studies com-
paring cell proliferation, Ki67 (MIB1), and estrogen and
progesterone receptor levels (ERa, PRA, and PRB) in the
breast terminal duct lobular units of oocyte donors, women
in early pregnancy, and in normally cycling women. Breast
tissue and blood samples were obtained from 10 oocyte
donors, and 30 pregnant women at 5–18 weeks of gesta-
tion. Breast tissue samples were also obtained from 26
normally cycling women. In the oocyte donors: peak E2
(mean *15,300 pmol/l) was reached on the day before
oocyte (and tissue) donation; peak progesterone (P4; mean
36.3 nmol/l) was reached on the day of donation; Ki67 was
positively associated with level of E2, and the mean Ki67
was 7.0% signiﬁcantly greater than the mean 1.8% of
cycling women. In the pregnant women: mean E2 rose
from *2,000 pmol/l at 5 weeks of gestation to
*27,000 pmol/l at 18 weeks; mean P4 did not change
from *40 nmol/l until around gestational week 11 when it
increased to *80 nmol/l; mean Ki67 was 15.4% and did
not vary with gestational age or E2. Oocyte donors have
greatly increased levels of E2 and of breast-cell prolifera-
tion, both comparable in the majority of donors to the
levels seen in the ﬁrst trimester of pregnancy. Whether
their short durations of greatly increased E2 levels are
associated with any long-term beneﬁcial effects on the
breast, as occurring in rodent models, is not known.
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Introduction
Estradiol (E2) and progesterone (P4) are critically impor-
tant in the pathogenesis of breast cancer [1, 2]. Infertility
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are known to cause a transient large increase in serum E2
comparable to the levels seen in the ﬁrst trimester of
pregnancy, whereas P4 levels are no greater than those that
are seen in the luteal phase of the menstrual cycle [3, 4].
The effects of this short-term high endogenous E2 exposure
on normal breast tissue are unknown.
As part of studies of the changes in human breast
associated with pregnancy, we have studied breast tissue
from naturally cycling nulliparous and parous women and
from women immediately after a pregnancy termination
[5]. We report here our studies of the epithelium of the
breast terminal duct lobular unit (TDLU) at the end of the
ovarian stimulation phase in 10 oocyte donors (women
having ovarian hyperstimulation to donate oocytes for use
by other women). We report on proliferation (Ki67),
estrogen receptor a (ER a), and progesterone receptors A
and B (PRA and PRB) in these oocyte donors, and compare
these results to those obtained from 30 women sampled
between 5 and 22 weeks of gestation (weeks since last
menstrual period, LMP) [5] and to the results obtained
from 26 cycling women.
Materials and methods
All study protocols described here were approved by the
Institutional Review Boards (IRBs) of the USC Keck
School of Medicine and where appropriate of the Depart-
ment of Defense Congressionally Directed Breast Cancer
Research Program. The prospectively collected samples
were obtained after the women had signed an informed
consent. The samples obtained retrospectively from the
cycling women were used after the women had been con-
tacted and given consent for their samples to be used.
Oocyte donors
Women attending the In vitro Fertilization Clinic at the
University of Southern California (USC) to donate oocytes
for the use of other women were invited to volunteer for
this study. Women who expressed a desire to participate
underwent a routine clinical breast examination; no
abnormalities were found. The research-related procedures
included a menstrual and reproductive history question-
naire, a blood sample on the day of oocyte retrieval and a
breast biopsy immediately after the oocyte retrieval or on
the day before if necessary.
Subjects underwent standard clinical protocols for
ovarian stimulation. Daily subcutaneous injections of fol-
licle stimulating hormone for approximately 10–14 days
with regular monitoring of serum E2 and ultrasound mea-
surement of ovarian follicles. When the follicles were
determined to be mature, human chorionic gonadotropin
(10,000 IU) was administered by subcutaneous injection
and oocytes were retrieved under intravenous sedation by
trans-vaginal ultrasound guided needle aspiration approxi-
mately 36 h later.
Ultrasound guided 14-gauge core-needle breast biopsy
tissue was collected from a region of ultrasonographically
normal dense breast tissue in the upper outer quadrant of
the breast. Samples of these tissues were formalin ﬁxed
parafﬁn embedded (FFPE) in a routine manner at the USC
Department of Pathology.
Pregnant women
The recruitment of pregnant women has been described
previously [5]. Brieﬂy, the pregnant samples were col-
lected from women who had undergone a pregnancy ter-
mination within the preceding 10 min; and the blood and
tissue samples were collected and processed in like manner
to that described above for oocyte donors.
Normally cycling women
The recruitment of normally cycling women has also been
described previously [5]. Brieﬂy, the samples from cycling
women were obtained from women undergoing a reduction
mammoplasty; some of these samples were collected pro-
spectively and others from FFPE tissue blocks, that had
been routinely processed at the USC Department of
Pathology. These were much larger tissue samples than are
obtained at core-needle biopsy but were processed in like
manner. No blood samples were obtained at the time of
surgery from the retrospectively identiﬁed women and
hormone values are not reported on here for the cycling
women.
Immunohistochemistry
Immunohistochemical (IHC) analysis of the FFPE samples
was performed as follows: Multiple adjacent FFPE sections
were cut at 5 lm, deparafﬁnized and hydrated. All slides
were subject to antigen retrieval which was performed by
heating the slides in 10 mmol/l sodium citrate buffer (pH
6) at 110C for 30 min in a pressure cooker in a microwave
oven. Endogenous peroxidase activity was blocked by
incubation in 3% H2O2 for 20 min, followed by blocking of
nonspeciﬁc sites with SuperBlock blocking buffer (Pierce,
Rockford, IL, USA) for 1 h both at room temperature (see
[5]).
The sections were incubated with the following anti-
bodies: MIB1, a proliferation marker, the mouse mono-
clonal antihuman Ki67 antibody (Dako Cytomation,
Carpenteria, CA, USA) at a concentration of 1:500; PRA,
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123the mouse monoclonal antibody NCL-PGR-312 (Novo-
castra Laboratories Ltd, Newcastle upon Tyne, UK) at a
concentration of 1:5,000; PRB, the mouse monoclonal
antibody NCL-PGR-B (Novocastra Laboratories Ltd,
Newcastle upon Tyne, UK) at a concentration of 1:100; and
ERa, the mouse monoclonal antibody ER Ab-12 (Clone
6F11) (Neomarkers, Kalamazoo, MI, USA) at a concen-
tration of 1:100. After incubation with the primary anti-
bodies, antibody binding was localized with the secondary
antibody for 45 min and then with the ABC staining kit
from Vector Laboratories (Burlingame, CA, USA)
according to the manufacturer’s instructions, and peroxi-
dase activity was detected using 3,30-diaminobenzidine
substrate solution (DAB; Biocare, Concord, CA, USA). A
wash step with phosphate buffer solution (PBS) for 10 min
was carried out between each step of the immunostaining.
Slides were counterstained with hematoxylin and mounted
in mounting medium for examination.
We generally assessed all TDLUs on a single slide. A
clear distinction between luminal-epithelial cells and
myoepithelial cells in TDLUs is frequently difﬁcult to
make on conventionally stained slides. For this reason we
counted the total numbers of luminal-epithelial ? myoep-
ithelial cells (epithelial cells) and the percentage of them
positive for the relevant marker using the Automated
Cellular Imaging System II (ACIS II, Clarient, Aliso Viejo,
CA, USA), which digitizes the images and permits the user
to identify and quantitate relevant areas on a high-resolu-
tion computer screen based on color differentiation. The
ACIS II software program does not function optimally
when both nuclear and cytoplasmic staining is present. Due
to some background cytoplasmic staining in addition to
nuclear positivity found in the ERa slides from the preg-
nant subjects, we used conventional light microscopy and
manual counting for assessing the TDLUs in these cases;
we counted 500 epithelial cells except in a few cases with
scant epithelial tissue. Only nuclear staining was regarded
as positive staining.
Blood specimens
The blood specimens obtained during oocyte stimulation
and at breast biopsy were processed in a standard manner
and the serum frozen at -20C. E2 and P4 were quantiﬁed
by speciﬁc radioimmunoassay as described previously [6,
7]. SHBG was measured by a chemiluminescent immu-
noassay on the Immulite Analyzer (Siemens Medical
Solutions Diagnostics, Malvern, PA, USA). The coefﬁ-
cients of variation for E2, P4 and SHBG were 14.7, 7.8,
and 3.7%, respectively. No serum results were given in our
previous publication on pregnant and naturally cycling
women [5]. Non-SHBG-bound E2 was calculated by the
method of So ¨derga ˚rd et al. [8] using the parameters given
by Dunn et al. [9].
Statistical analysis
We analyzed these data using the standard statistical
package program, Stata 11 (Stata Corporation, College
Station, TX, USA). Differences in expression and tests for
trend in expression were tested for signiﬁcance by standard
t tests and regression tests after transformation of the
variables to achieve more normal distributions of values
(square root transformations of ERa, PRA, and PRB; and
logarithmic transformation of MIB1) [5]. E2, P4, and
SHBG values were logarithmically transformed. Testing
for the effects of prior births, age and ethnicity on the
results were carried out by inclusion of terms for these in
regression analyses. All statistical signiﬁcance levels
(P values) quoted are two sided.
Results
We recruited 13 oocyte donors who provided informed
consent. One decided to withdraw from the study prior to
undergoing the breast biopsy. The remaining 12 completed
the study protocol. The biopsies from two of the women
had no epithelium in the specimen—these women were
excluded from further study. Of the remaining 10, eight
had their biopsy on the day of oocyte donation and two on
the day before due to their unavailability on the donation
day.
Figure 1 shows the E2 and P4 values of the individual
subjects in the 7 days before oocyte retrieval. E2 increased
steadily in each subject until the day before oocyte retrie-
val—on the day of retrieval, E2 had fallen from a mean of
*15,300 to *6,000 pmol/l. P4 also increased steadily in
each subject; the mean value increased from 1.1 nmol/l at 7
days before oocyte retrieval to 4.1 nmol/l at 2 days before
retrieval, and then, after hCG treatment, to 18.0 nmol/l on
the day before oocyte retrieval, and to 36.3 nmol/l on the
day of retrieval. For comparison, in naturally cycling
women, the follicular phase maximum E2 is *1,100 pmol/
l, the luteal phase maximum E2 is *510 pmol/l, and the
luteal phase maximum P4 is *40 nmol/l [10].
Figure 2 shows the relationships of serum E2 and P4 to
gestational age in the pregnant women [5]. E2 increased
steadily with gestational age, from *2,000 pmol/l at
5 weeks to *27,000 pmol/l at 18 weeks of gestation. P4
did not change from the mid-luteal peak of *40 nmol/l
until around week 11 of gestation, after which it increased
to *80 nmol/l.
Figure 3 shows the relation between Ki67 (MIB1) for
the oocyte donors plotted against their E2 on the day before
Breast Cancer Res Treat (2012) 132:653–660 655
123biopsy, and for the 30 pregnant women plotted against their
E2 on the day of biopsy, while Fig. 4 shows the relation
between Ki67 for the 10 oocyte donors and the 30 pregnant
women plotted against their P4 on the day of biopsy.
For the oocyte donors, there was a strong positive
relationship between Ki67 and E2 on the day before biopsy
(see Fig. 3)—correlation, r = 0.76 (P = 0.010); while the
correlation between Ki67 and E2 on the day of biopsy was
much weaker—r = 0.17 (P = 0.65) (data not shown). For
the oocyte donors, there was no signiﬁcant relationship
between Ki67 and P4 on the day of biopsy or P4 on the day
before biopsy. For the pregnant women, there was no
relationship between Ki67 and E2 or P4.
The means (and 95% conﬁdence intervals) of the pro-
portion of epithelial cells with positive nuclear staining for
Ki67, ERa, PRA, and PRB are given in Table 1.
The Ki67 mean value was increased from 1.8% in the
cycling women to 7.0% in the oocyte donors (P = 0.003).
The Ki67 mean value in the seven oocyte donors whose
serum E2 values on the day before biopsy exceeded
10,000 pmol/l was 14.1%, very close to the mean value of
15.4% seen in the pregnant women.
The ERa mean value was lower in oocyte donors (6.8%)
than in cycling women (12.0%). The PRA mean value was
slightly lower in the oocyte donors (17.8%) than in the
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Fig. 1 Individual oocyte donor estradiol (E2) and progesterone (P4)
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Fig. 2 Individual pregnant woman estradiol (E2) and progesterone


































Fig. 3 Individual woman TDLU epithelial cell MIB1 values versus
estradiol (E2) values—E2 values for oocyte donors on the day before
biopsy (ﬁlled circle); E2 values for ‘‘pregnant’’ women on the day of
biopsy (open square)
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123pregnant women (3.9%). The difference between the
oocyte donors and the cycling women was not statistically
signiﬁcant. The PRB mean values were similar in all three
groups of women.
The results shown in Table 1 are the values as measured
without adjustment for the potential confounders of parity,
age, or ethnicity. Adjustment for ethnicity and age had
little effect on any of the values shown. We previously
reported that parous naturally cycling women had signiﬁ-
cantly lower PRA values than nulliparous naturally cycling
women [5], and lower values of Ki67, ERa, and PRB, but
the differences for these factors were not statistically sig-
niﬁcant. Parity had no effect on Ki67, ERa, and PRA in
pregnant women, but the PRB mean was marginally sta-
tistically signiﬁcantly greater in the parous group
(P = 0.049). Eight of the 10 oocyte donors were nullipa-
rous, so that we had no power to investigate the effects of
parity in the oocyte donors. Adjustment for parity made
little difference to the comparisons shown in Table 1 and
no differences to the statistical signiﬁcance of the
comparisons.
Discussion
This is the ﬁrst study, to our knowledge, to evaluate the
immediate effects of short-term exposure to high levels of
endogenous estrogen on the breast epithelium of women. In
oocyte donors, the level of breast-cell proliferation was
positively associated with their serum E2, and a large
increase in breast-cell proliferation, similar to the increase
seen in pregnant women, occurred in six of the seven
oocyte donors whose serum E2 exceeded 10,000 pmol/l. In
contrast, the pregnant women demonstrated the same level
of breast-cell proliferation over the whole range of
observed serum E2 values from *1,800 pmol/l to
*30,000 pmol/l with no evidence of a dose–response.
When we re-plotted Fig. 3 using non-SHBG-bound E2
rather than E2, a very similar picture was seen. It is unli-
kely that the contribution of estriol (E3) and estetrol (E4) to
the overall estrogenic milieu in pregnant women explains
their higher proliferation because these two hormones are
at very low levels through gestational week 8 where most
of our subjects with E2 concentrations below 10,000 pmol/
l lie (Fig. 3 [11–13]). Higher levels of proliferation in
pregnant women may be due to their longer exposure to
high levels of E2 and to longer exposure to luteal (or
higher) levels of P4, it may also be due to their higher ERa
expression (see below).
Prolactin is a breast-cell mitogen and prolactin levels
increase starting around week 5 of gestation [14]. The
proliferation effect of E2 may be enhanced as prolactin has
been reported to induce estrogen receptor expression in the
breast [15, 16]. Prolactin levels vary greatly during the day
with a maximum during sleep and a rapid fall-off on
waking. Time of blood draw was not recorded for our study
subjects and therefore does not provide useful information
on the comparison of prolactin levels in oocyte donors and
pregnant women.
We previously reported that PRA decreased steadily
with gestational age in pregnant women [5] and although
there was already some decrease early on in pregnancy,
PRA only reached very low levels (*1%) after week 12 of
gestation. There was a non-statistically signiﬁcant 24%
reduction of PRA in oocyte donors compared with natu-




































Fig. 4 Individual woman TDLU epithelial cell MIB1 values versus
progesterone (P4) values on day of biopsy—oocyte donors (ﬁlled
circle); ‘‘pregnant’’ women (open square)
Table 1 Mean (with 95% conﬁdence limits) percentages of Ki67,







Ki67 Oocyte donor (N = 10) 7.0 3.0 16.5
Pregnant (N = 30) 15.4 12.4 19.1 0.016
Cycling (N = 26) 1.8 1.2 2.7 0.003
ERa Oocyte donor 6.8 4.3 9.9
Pregnant 11.0 7.9 14.6 0.15
Cycling 12.0 9.2 15.2 0.034
PRA Oocyte donor 17.8 13.4 22.9
Pregnant 3.9 2.5 5.5 \0.001
Cycling 23.5 16.2 32.2 0.37
PRB Oocyte donor 16.9 11.3 23.6
Pregnant 12.8 9.4 16.8 0.31
Cycling 19.2 13.3 26.0 0.67
a Calculations were made with transformed values—logarithmic for
MIB1, and square root for ERa, PRA, and PRB values. lcl and ucl are
lower and upper 95% conﬁdence interval values, respectively
b P values are for comparisons with oocyte donors
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123reduction seen in pregnant women. We also previously
reported that ‘‘overall there was little difference in ERa
expression between non-pregnant and pregnant subjects,’’
but the data strongly suggested that ‘‘ERa expression is
increased early on in pregnancy (\8 weeks of gestation)
and then declines to lower levels than are seen in non-
pregnant subjects.’’ In contrast, ERa expression in oocyte
donors was low.
Based on a strictly limited amount of epidemiological
data but considerable data from rodent experiments (see
below), it is possible that a short-term pregnancy and
short-term relatively high levels of estrogen may provide
some long-term protection against breast cancer. How-
ever, the fetoplacental unit in pregnant women is
responsible for major endocrinologic changes which are
not present in women undergoing ovarian stimulation.
Thus, a number of factors in a pregnant woman may
contribute to long-term protection against breast cancer.
The effects of the high levels of endogenous E2 and P4
achieved during human full-term pregnancy are twofold: a
transient increase in breast cancer risk and this is fol-
lowed by a signiﬁcant long-term permanent decrease in
risk if the pregnancy occurs before around age 32, with
the protective effect being greater the earlier the age at
which the pregnancy occurs [16–21]. The mechanism for
the protective effect remains unclear, but has been
attributed in part to hormonal changes, in particular, a
reduction in prolactin levels [1], and may possibly be due
to hormone-induced changes in breast function leading to
lower breast-cell proliferation and possibly other effects.
Breast-tissue mRNA expression differences between par-
ous and nulliparous rodents have been observed [22, 23],
but whether such changes occur in humans has not been
satisfactorily established. There is some evidence that
terminated pregnancies may also provide some degree of
protection against breast cancer [24]. There are no data
available on the effects of a terminated pregnancy on
long-term prolactin levels, breast-cell proliferation, or any
other possibly relevant factors.
Full-term pregnancy-induced protection against mam-
mary carcinogenesis is consistently observed in rats [25–
27]. There is again some evidence that terminated preg-
nancies may also provide protection [26], but this has not
been found consistently [27]. The protective effect in the
rat can also be achieved by administration of exogenous E2
and P4 [25, 28–30], and two studies have found that with
E2 ? P4 substantial protection could be achieved with as
little as 7–10 days of administration [29, 30].
There are large differences in the effects of pregnancy in
women and in the rat: the ovary is the sole source of serum
estrogen and the major source of serum progesterone in
pregnancy in the rat, while in women, the main source of
estrogen and progesterone moves from the ovary to the
placenta during the latter part of the ﬁrst trimester [31, 32].
The serum E2 levels in pregnant rats only exceed the
values seen in cycling rats during the third week of preg-
nancy, when it approximately doubles [33–37]. In contrast,
the levels of serum E2 are greatly increased in pregnant
women—they are increased some ﬁvefold in the ﬁrst tri-
mester, some 20-fold in the second trimester, and some
40-fold in the third trimester [31]. Whether the results in
the rat of short-term E2 exposure at only twice the maxi-
mum estrus serum E2 level are of any relevance to the
human situation is, thus, not at all clear.
The serum P4 levels in cycling rats vary from 45 to
160 nmol/l [34–36]; the levels steadily increase during
pregnancy and reach a maximum of 320 nmol/l in the
second week, approximately double the maximum seen in
the estrus cycle, and then decline in the third week [38, 39].
The levels of serum P4 in cycling women are lower, at
1.5–40 nmol/l, than the levels in the cycling rat [10].
Serum P4 levels in women increase steadily during preg-
nancy—they are increased some twofold in the ﬁrst tri-
mester, some fourfold in the second trimester, and some
10-fold in the third trimester compared to the maximum of
around 40 nmol/l at the luteal-phase serum P4 peak [31].
The maximum seen during pregnancy in women is thus not
greatly increased over the maximum level seen in the rat
estrus cycle, and the results in the rat of short-term P4
exposure at the maximum estrus cycle serum P4 level
could possibly be of more relevance to the human situation.
If short-term high levels of serum E2 do provide long-
term protection against breast cancer, then we might expect
that the breast would change in oocyte donors in a way
similar to that seen in pregnant women. The short-term
high levels of endogenous E2 did cause a dramatic increase
in breast-cell proliferation similar to that associated with
pregnancy, but the reduction in PRA was much less than
that seen in pregnant women. Studies comparing nullipa-
rous oocyte donors at some time after donation to parous
women should be informative.
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